MABPHARM LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.415 HKD | 0.00% |
|
-2.35% | -9.78% |
| 03-26 | Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 01-10 | Livzon Pharma Recognizes Credit, Asset Impairments | MT |
| Sales 2022 | 55.92M 7.72M 60.41M 618M | Sales 2023 | 87.16M 12.03M 94.17M 963M | Capitalization | 1.72B 238M 1.86B 19.06B |
|---|---|---|---|---|---|
| Net income 2022 | -211M -29.12M -228M -2.33B | Net income 2023 | -209M -28.84M -226M -2.31B | EV / Sales 2022 | 30.5 x |
| Net Debt 2022 | 123M 16.94M 133M 1.36B | Net Debt 2023 | 109M 15.07M 118M 1.21B | EV / Sales 2023 | 21 x |
| P/E ratio 2022 |
-7.52
x | P/E ratio 2023 |
-8.24
x | Employees | 347 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 22.82% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -2.35% | ||
| Current month | -16.16% | ||
| 1 month | -17.00% | ||
| 3 months | +20.29% | ||
| 6 months | -8.79% | ||
| Current year | -9.78% |
1 week
0.42
0.45
1 month
0.420.50
Current year
0.250.50
1 year
0.250.95
3 years
0.251.40
5 years
0.251.80
10 years
0.251.80
| Managers | Title | Age | Since |
|---|---|---|---|
Hao Wang
CEO | Chief Executive Officer | 55 | 19/07/18 |
Yun Feng Li
DFI | Director of Finance/CFO | 47 | 19/07/18 |
Tao Jing
BRD | Director/Board Member | 51 | 02/08/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shu Ge Jiao
CHM | Chairman | 58 | 19/07/18 |
Ho Ming Leung
BRD | Director/Board Member | 41 | 16/06/22 |
Wei Zhu Qian
FOU | Founder | 48 | 03/02/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.415 | 0.00% | 0 |
| 25/04/24 | 0.415 | -7.78% | 50,000 |
| 24/04/24 | 0.45 | +5.88% | 2,000 |
| 23/04/24 | 0.425 | 0.00% | 0 |
| 22/04/24 | 0.425 | 0.00% | 62,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Mabpharm Ltd is China-based company mainly engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company's main products include omalizumab (CMAB007), cetuximab (CMAB009) and infliximab (CMAB008). The Company mainly conducts its businesses in China market.
Calendar
22/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.78% | 219M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 2181 Stock
